With a staggering 92% failure rate in drug discovery and development, the pharmaceutical industry faces monumental challenges. Conventional approaches incur a massive annual expense of $53 billion due to unsuccessful animal testing.
The urgency of this issue is underscored by recent revolutionary legislation in the US, which removes the 83-year-old mandate for animal studies in new drug licensing. This shift sets the stage for innovative approaches like the one pioneered by Quris - the first Bio-AI clinical-prediction platform.
Dr. Bentwich will explore how Quris is revolutionizing drug safety prediction, combining advanced AI with patient-on-chip technology. This unique synergy facilitates millions of interactions between known drugs and miniaturized human organs on a chip, generating vast amounts of auto-labelled nano-sensor data. This data is then used to train AI models, enabling the platform to predict the safety and efficacy of new drug candidates with high accuracy, significantly reducing the time and cost associated with traditional animal testing.
The presentation will provide an in-depth look at this three-tiered process and its potential to indicate drug toxicity accurately. By integrating cutting-edge machine learning, real-time nano-sensing, and stem-cell genomic diversity technologies, Quris is not just advancing drug development but is also a key player in the modernization of the field.